Novartis To Acquire Avidity Biosciences In $12 Bln Deal

Novartis AG has agreed to acquire Avidity Biosciences Inc. for approximately $12.0 billion, or $72.00 per share, representing a 46% premium, to gain Avidity's neuroscience pipeline and its RNA-targeting delivery platform, including three late-stage clinical programs for Duchenne, myotonic, and facioscapulohumeral muscular dystrophies. As part of the deal, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded entity, SpinCo, capitalized with $270 million, with Avidity shareholders receiving SpinCo shares. The acquisition is anticipated to close in the first half of 2026, pending regulatory approvals and shareholder consent.

Analysis

Novartis AG has entered into a definitive agreement to acquire Avidity Biosciences Inc. for $12.0 billion, or $72.00 per share in cash, representing a substantial 46% premium over Avidity's October 24, 2025 closing price. This strategic acquisition aims to integrate Avidity's neuroscience pipeline and its differentiated RNA-targeting delivery platform, including three late-stage clinical programs for Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD).

As part of the transaction, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded entity, SpinCo, capitalized with $270 million. SpinCo will retain rights to Avidity's proprietary RNA platform for cardiology applications, including existing collaborations with Bristol Myers Squibb and Eli Lilly, with Avidity shareholders receiving one share of SpinCo for every ten Avidity shares held.

The deal, unanimously approved by both companies' boards, is expected to close in the first half of 2026, subject to regulatory approvals, shareholder consent, and the completion of the SpinCo separation. The market sentiment surrounding this M&A activity is strongly positive (0.85), indicating an optimistic outlook on the strategic value and potential impact of the combined entities.

Key Decisions for Investors

• Avidity (RNA) shareholders should evaluate the immediate cash premium of $72.00 per share and the future potential of the SpinCo shares received, considering the 46% premium over recent trading.
• Novartis (NVS) investors should assess the long-term strategic benefits of integrating Avidity's late-stage neuroscience pipeline and RNA platform against the $12.0 billion acquisition cost and potential integration challenges.
• Investors should closely monitor the regulatory approval process and the successful separation of SpinCo, as these are critical conditions for the transaction's completion by H1 2026.